

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release (N.B. if exact date is not specified in NICE documentation, the last day of the month published will be employed)	Adherence of local formulary to NICE				
		Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. Additional stipulations, rationale, method of making available)
Tofacitinib for moderate to severe rheumatoid arthritis [TA480]	11/10/2017	X		19/10/2017	8	
Reslizumab for treating severe eosinophilic asthma [TA479]	04/10/2017	X		17/10/2017	13	
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma [TA478]	04/10/2017	X		17/10/2017	13	
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer [TA476]	06/09/2017	X		17/10/2017	41	
Dimethyl fumarate for treating moderate to severe plaque psoriasis [TA475]	06/09/2017	X		21/09/2017	15	
Sorafenib for treating advanced hepatocellular carcinoma [TA474]	06/09/2017	X		17/10/2017	41	
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck [TA473]	31/08/2017	X		17/10/2017	47	
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [TA472]	30/08/2017	X		17/10/2017	48	
Eluxadoline for treating irritable bowel syndrome with diarrhoea [TA471]	30/08/2017	X		21/09/2017	22	
Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) [TA470]	23/08/2017		X	23/08/2017	0	
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) [TA469]	23/08/2017		X	23/08/2017	0	
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) [TA468]	23/08/2017		X	23/08/2017	0	
Holoclar for treating limbal stem cell deficiency after eye burns [TA467]	16/08/2017		X	16/08/2017	0	
Baricitinib for moderate to severe rheumatoid arthritis [TA466]	09/08/2017	X		21/09/2017	43	
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma [TA465]	09/08/2017	X		17/10/2017	69	
Bisphosphonates for treating osteoporosis [TA464]	09/08/2017	X		21/09/2017	43	
Cabozantinib for previously treated advanced renal cell carcinoma [TA463]	09/08/2017	X		17/10/2017	69	

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma [TA462]	26/07/2017	X		17/10/2017	83	
Roflumilast for treating chronic obstructive pulmonary disease [TA461]	26/07/2017	X		17/08/2017	22	
Adalimumab and dexamethasone for treating non-infectious uveitis [TA460]	26/07/2017	X		17/10/2017	83	
Collagenase clostridium histolyticum for treating Dupuytren's contracture [TA459]	26/07/2017	X		17/08/2017	22	
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [TA458]	19/07/2017	X		17/10/2017	90	
Carfilzomib for previously treated multiple myeloma [TA457]	19/07/2017	X		17/10/2017	90	
Ustekinumab for moderately to severely active Crohn's disease after previous treatment [TA456]	12/07/2017	X		17/08/2017	36	
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people [TA455]	12/07/2017	X		17/08/2017	36	
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA454]	05/07/2017		X	05/07/2017	0	
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) [TA453]	05/07/2017		X	05/07/2017	0	
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) [TA452]	05/07/2017		X	05/07/2017	0	
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma [TA446]	28/06/2017	X		11/07/2017	13	
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA447]	28/06/2017	X		11/07/2017	13	
Etelcalcetide for treating secondary hyperparathyroidism [TA448]	28/06/2017	X		11/07/2017	13	
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease [TA449]	28/06/2017	X		11/07/2017	13	
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia [TA450]	28/06/2017	X		11/07/2017	13	
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia [TA451]	28/06/2017	X		11/07/2017	13	
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA444]	24/05/2017		X	24/05/2017	0	
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA445]	24/05/2017	X		15/06/2017	22	

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine [TA440]	26/04/2017		X	26/04/2017	0	
Daclizumab for treating relapsing–remitting multiple sclerosis [TA441]	26/04/2017	X		11/07/2017	76	
Ixekizumab for treating moderate to severe plaque psoriasis [TA442]	26/04/2017	X		18/05/2017	22	
Obeticholic acid for treating primary biliary cholangitis [TA443]	26/04/2017	X		11/07/2017	76	
		31	9			
		% "Yes"	% "N/A"	–	Average implement time	
Adherence statistics for 2017-18		77.5%	22.5%		30	